New eczema drug candidate enters first human safety tests
NCT ID NCT06920693
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests the safety of a new drug called GB-7624 in 40 healthy adults. It is the first time this drug is being given to humans. The study gives single or multiple doses under the skin to see if it is safe and how the body processes it. If successful, it may eventually be developed as a treatment for atopic dermatitis (eczema).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GB-7624
What this could lead to
If safe, this could lead to a new treatment option for atopic dermatitis (eczema) that helps control the condition.
What could go wrong
This is a very early, small study in healthy people, not patients. It only tests safety and dosing, not whether it works for eczema. Many drugs fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Generate Biomedicines Clinical Site
Herston, Queensland, 4007, Australia